Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Ascending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68001-0611-33 68001-0611 Zoledronic acid Zoledronic acid 5.0 mg/100mL Ancillary Therapy Bisphosphonate Intravenous May 3, 2024 In Use
68788-8433-01 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8433-03 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8433-06 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8433-09 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8651-01 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8651-02 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8651-03 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8651-05 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8651-06 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8666-01 68788-8666 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 14, 2024 In Use
68788-8666-03 68788-8666 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 14, 2024 In Use
43598-0671-11 43598-0671 Fosaprepitant Fosaprepitant 150.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 20, 2020 In Use
60687-0386-21 60687-0386 DRONABINOL DRONABINOL 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral Aug. 9, 2018 Oct. 31, 2025 In Use
60687-0386-94 60687-0386 DRONABINOL DRONABINOL 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 31, 2024 In Use
64950-0344-16 64950-0344 Metoclopramide Hydrochloride Metoclopramide 5.0 mg/5mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Oral June 1, 2024 In Use
66220-0637-31 66220-0637 Granisetron SANCUSO 3.1 mg/24h Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Transdermal July 16, 2024 In Use
68083-0155-01 68083-0155 Plerixafor Plerixafor 24.0 mg/1.2mL Ancillary Therapy Immunostimulant Stem Cell Mobilizer Subcutaneous May 3, 2024 In Use
70121-2631-01 70121-2631 FOSAPREPITANT DIMEGLUMINE FOCINVEZ 150.0 mg/50mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous June 15, 2024 In Use
70518-4145-00 70518-4145 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 18, 2024 In Use
72162-1878-06 72162-1878 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 30, 2023 In Use
72162-1878-01 72162-1878 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 30, 2023 In Use
72266-0152-01 72266-0152 Zoledronic acid Zoledronic acid 5.0 mg/100mL Ancillary Therapy Bisphosphonate Intravenous June 12, 2023 In Use
75907-0047-30 75907-0047 Cyclosporine Cyclosporine 25.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral July 1, 2024 In Use
82448-0100-14 82448-0100 Nirogacestat OGSIVEO 100.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov. 27, 2023 In Use
82448-0150-14 82448-0150 Nirogacestat OGSIVEO 150.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov. 27, 2023 In Use
82449-0231-01 82449-0231 FOSAPREPITANT DIMEGLUMINE FOCINVEZ 150.0 mg/50mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous June 26, 2024 In Use
83634-0777-05 83634-0777 Palonosetron hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 15, 2024 In Use
83634-0779-02 83634-0779 Metoclopramide hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous June 30, 2024 In Use
83703-0531-02 83703-0531 Palonosetron hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov. 12, 2021 In Use
17856-0691-01 17856-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 17, 2024 In Use
17856-0691-02 17856-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 17, 2024 In Use
17856-0691-04 17856-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 17, 2024 In Use
17856-0691-05 17856-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 17, 2024 In Use
17856-0691-06 17856-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 17, 2024 In Use
17856-0691-07 17856-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 17, 2024 In Use
17856-0691-08 17856-0691 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 17, 2024 In Use
00078-0110-22 00078-0110 Cyclosporine Sandimmune 100.0 mg/mL Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral Nov. 14, 1983 Dec. 31, 2025 In Use
00409-2504-10 00409-2504 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Nov. 14, 2018 June 30, 2025 In Use
00904-7144-61 00904-7144 Dronabinol Dronabinol 2.5 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 Aug. 31, 2025 In Use
00904-7145-04 00904-7145 Dronabinol Dronabinol 5.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral March 3, 2021 Aug. 31, 2025 In Use
16714-0815-01 16714-0815 Zoledronic Acid Zoledronic Acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous May 30, 2018 Aug. 31, 2025 In Use
59676-0302-00 59676-0302 Erythropoietin Procrit 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0302-01 59676-0302 Erythropoietin Procrit 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0302-02 59676-0302 Erythropoietin Procrit 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Jan. 8, 2014 In Use
59676-0303-00 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0303-01 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use
59676-0303-02 59676-0303 Erythropoietin Procrit 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 Jan. 8, 2014 In Use
59676-0304-00 59676-0304 Erythropoietin Procrit 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 8, 2011 In Use
59676-0304-01 59676-0304 Erythropoietin Procrit 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 1, 1989 In Use

Found 10,000 results in 4 milliseconds — Export these results